---
title: "Gilead Sciences: Diversification Strategy Not Derisked Enough Yet"
date: "2025-02-11 11:04:38"
summary: "Sundry Photography  Investment Thesis Gilead Sciences (NASDAQ:GILD) is a market leader for HIV drug manufacturing, urgently diversifying its product portfolio as its blockbuster drugs lose exclusivity in 2033. At $85, the stock would price in 2% revenue growth, which would be in line with"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Gilead Sciences, Inc. headquarters in Silicon Valley](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750) 



Sundry Photography





Investment Thesis
-----------------

Gilead Sciences (NASDAQ:[GILD](https://seekingalpha.com/symbol/GILD "Gilead Sciences, Inc.")) is a market leader for HIV drug manufacturing, urgently diversifying its product portfolio as its blockbuster drugs lose exclusivity in 2033. At $85, the stock would price in 2% revenue growth, which would be in line with

[seekalpha_articles](https://seekingalpha.com/article/4756849-gilead-sciences-diversification-strategy-not-derisked-enough-yet)
